VEEV stock climbs 36% YTD as it accelerates its shift off Salesforce, betting on Vault to power future growth in life sciences.

As Merck gears up for its Q2 earnings, all eyes are on Keytruda, its oncology superstar. Keytruda, accounting for nearly half of Merck’s pharma sales, is anticipated to report Q2 sales of $7.90 ...